Identification of anti-Parkinson's Disease Lead Compounds from Aspergillus ochraceus Targeting Adenosin Receptors A2A

Two novel alkaloids compounds together with fifteen know metabolites were identified from Aspergillus ochraceus. The stereochemistry features of the new molecules were determined via HRESIMS, NMR, ECD, and XRD analyses. Amongst these, compounds two compounds exhibited potential efficacy as anti-Parkinson's disease with the EC50 values of 2.30 and 2.45 mu M, respectively. ADMET prediction showed that these compounds owned favorable drug-like characteristics and safe toxicity scores towards CNS drugs. Virtual screening analyses manifested that the compounds exhibited not only robust and reliable interactions to adenosine receptors A(2A), but also higher binding selectivity to A(2A) receptors than to A(1) and A(3) receptors. Molecular dynamics simulation demonstrated the reliability of molecular docking results and the stability of the complexes obtained with the novel compounds and A(2A) receptors in natural environments. It is the first time that anti-PD lead compounds have been identified from Aspergillus ochraceus and targeting adenosine A(2A) receptors.

Automated summary

In this study, two novel alkaloid compounds with anti-Parkinson's disease potential were identified from Aspergillus ochraceus. These compounds exhibited favorable drug-like characteristics, high selectivity for binding to adenosine receptors A(2A), and reliable interactions, providing new insights for targeting this receptor for Parkinson's disease therapy.